Results 311 to 320 of about 464,951 (372)

Single‐component cationic polyethylenimine thermogel for sustained and localized gene delivery to combat multi‐drug resistant cancer

open access: yesBMEMat, EarlyView.
A cationic thermogelling copolymer employing branched PEI‐25 kDa as the sole hydrophilic segment can be facilely complexed with plasmid by physical mixing in the sol phase. Spontaneous gelation is achieved via self‐assembly after injection due to physiological temperature. Sustained and localized release of plasmid from the cationic PEI‐thermogel leads
Qianyu Lin   +11 more
wiley   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

open access: yesCancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae   +16 more
wiley   +1 more source

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

open access: yesCancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng   +32 more
wiley   +1 more source

High normal alanine aminotransferase is an indicator for better response to antiviral therapy in chronic hepatitis B. [PDF]

open access: yesFront Immunol
Cai C   +15 more
europepmc   +1 more source

Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis

open access: yesCancer Communications, EarlyView.
Abstract Background Colorectal cancer liver metastasis (CRLM) is characterized by an immunosuppressive microenvironment and a blunted response to immunotherapy. Notably, tumor‐associated macrophages (TAMs) play a critical role in modulating immune responses and exhibit significant heterogeneity in CRLM.
Yizhi Zhan   +11 more
wiley   +1 more source

Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study

open access: yesCancer Communications, EarlyView.
Abstract Background Cadonilimab is a humanized immunoglobulin G1 bispecific antibody targeting programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4). This study aimed to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) combined with cadonilimab in patients with advanced recurrent or ...
Yao Xiao   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy